Usha Rani Kandula

Mrs. Usha Rani Kandula


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
AWAddisu Dabi Wake
Addisu Dabi Wake
In 2019, coronavirus disease pandemic (COVID-19) influences the quality of life of health personnel who are on the front lines in dealing with COVID-19 patients. The purpose of this study is to assess the quality of life of health professionals during the COVID-19 epidemic. The novel coronavirus disease-19 (COVID-19) has spread across the globe with the direct causal viral agent of severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) and infected many people. All health professionals (HPs) such as physicians, nurses, and other allied health staff members are primary caregivers in hospitals and other health care settings, specifically under pandemic situations such as COVID-19. The emergence of the COVID-19 pandemic has caused numerous diversions in the preservation of the quality of life (QoL) of health professionals by deviations from normal physical, mental, and social wellbeing aspects. HPs are the most vulnerable population to COVID-19 viral transmission while delivering emergency medical services to persons infected with the virus in various health care sectors, such as direct engagement in lifesaving management. In this perspective, some recent literature on QoL of health professionals was examined, uncovering that they frequently experience fear and anxiety due to viral transmissions in the place of work and probable cross-contamination among family members, tend to experience insomnia caused by sudden increased work pressure, struggle to balance professional and personal life, suffering from mental health disturbances such as depressive episodes, mood disturbances, and suicidal tendencies due to the unpredictability of the disease outbreak. The current review is looking to determine and address the degree of QoL maintained by specific types of health professionals during critical moments of COVID-19 pandemics. This study may assist health organization stakeholders in enhancing QoL among health professionals by introducing required provisions, measures, or initiatives for the welfare of health professionals, notably in resolving pandemic demands in all health organizations.

1 January 2022 in Psychology Research and Behavior Management
Verified
Journal Article
Open access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
AWAddisu Dabi Wake
Addisu Dabi Wake
The pandemic outbreak, coronavirus disease 2019 (COVID-19) threatens proper family patterns by disrupting normal day-to-day activities, such as working patterns of parents by working from home, online children’s education rather than regular school, a dilemma in children’s education and health constrained movement by complete or partial home lockdowns to prevent disease spread, anxiety of disease spread, failure of home quarantine due to insufficient home situation and reduced personal protective equipment usage due to the extra financial burden, reduced social communications, increased health burdens than usual along with enormous toil with dependent family members, demands of financial burdens by multiple factors, reduced monthly income during pandemics, lack of employment or job insecurity, deviations in mental health among family members such as fear, anxiety, insomnia, severe depression, hetero aggression, child verbal or physical abuses, increased alcohol consumption and substance abuse or drug addictions, aggressive behavior, self-blaming or injury, unintentional suicidal tendencies, mood disorders, posttraumatic stress disorder and failure to meet health demands due to a lack of health facilities. Many contributing factors are affecting the normal family status than usual circumstances such as reduced hospital equipment or resources which is due to pandemic effects, social isolation due to outside quarantine measures, insecurity of the future and ongoing pandemic situation, fear of vaccination side effects, and so on. Therefore, we hope to raise awareness about the magnitude of parental stress levels and contributing factors. Moreover, these findings would encourage effective stress management to overcome the factors that contribute to parenteral stress and to improve coping skills to face the coming darkness with ease. It supports the preservation of physical, mental, and social well-being in families as well as minimizing or overcoming stressors, maintaining strong familial ties, and improving life expectancy globally during this pandemic.

1 January 2022 in Biologics: Targets and Therapy
Verified
Journal Article
Open access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
AWAddisu Dabi Wake
Addisu Dabi Wake
Stem cell therapies are becoming a major topic in biomedical research all over the planet. It may be a viable treatment choice for people suffering from a wide range of illnesses and injuries. It has recently emerged as an extremely intriguing and well -established science and research topic. Expectations have risen due to advancements in therapeutic approaches. Multiple laboratory testing of regulated stem cell culture and derivation is carried out before the formation of stem cells for the use of therapeutic process. Whereas HIV infection is contagious and can last a lifetime. Researchers are still working to develop a comprehensive and effective treatment for HIV and its associated condition, as well as AIDS. HIV propagation is primarily restricted to the immune system, notably T lymphocytes, as well as macrophages. Large numbers of research studies have contributed to a plethora of data about the enigmatic AIDS life cycle. This vast amount of data provides potential targets for AIDS therapies. Currently, stem cell transplantation, along with other procedures, provided novel insights into HIV pathogenesis and offered a glimpse of hope for the development of a viable HIV cure technique. One of its existing focus areas in HIV and AIDS research is to develop a novel therapeutic strategic plan capable of providing life-long complete recovery of HIV and AIDS without regular drug treatment and, inevitably, curative therapy for HIV and AIDS. The current paper tries to address the possibilities for improved stem cell treatments with "bone marrow, Hematopoietic, human umbilical cord mesenchymal, Genetical modifications with CRISPR/Cas9 in combination of stem cells, induced pluripotent stem cells applications" are discussed which are specifically applied in the HIV and AIDS therapeutic manage-ment advancement procedures.

1 February 2023 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
TTTechane Sisay Tuji
Techane Sisay Tuji
DGDinkinesh Begna Gudeta
Dinkinesh Begna Gudeta
KBKassech Leta Bulbula
Kassech Leta Bulbula
AMAnwar Abdulwahed Mohammad
Anwar Abdulwahed Mohammad
AAAhmad Abbas
Ahmad Abbas
Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

1 May 2023 in Biologics: Targets and Therapy
Verified
Journal Article
Open access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
AWAddisu Dabi Wake
Addisu Dabi Wake
Background: Global pandemic identified as coronavirus disease 2019 (COVID-19) has resulted in a variety of clinical symptoms, from asymptomatic carriers to those with severe acute respiratory distress syndrome (SARS) and moderate upper respiratory tract symptoms (URTS). This systematic review aimed to determine effectiveness of stem cell (SC) applications among COVID-19 patients. Methods: Multiple databases of PubMed, EMBASE, Science Direct, Google Scholar, Scopus, Web of Science, and Cochrane Library were used. Studies were screened, chosen, and included in this systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 flowchart diagram and PRISMA checklist. Included studies’ quality was assessed employing Critical Appraisal Skills Programme (CASP) quality evaluation criteria for 14 randomized controlled trials (RCTs). Results: Fourteen RCTs were performed between the years of 2020 to 2022, respectively, with a sample size n = 574 (treatment group (n = 318); control group (n = 256)) in multiple countries of Indonesia, Iran, Brazil, Turkey, China, Florida, UK, and France. The greatest sample size reported from China among 100 COVID-19 patients, while the lowest sample of 9 COVID-19 patients from Jakarta, Indonesia, and the patient’s age ranges from 18 to 69 years. Studies applied to the type of SC were “Umbilical cord MSCs, MSCs secretome, MSCs, Placenta-derived MSCs, Human immature dental pulp SC, DW-MSC infusion, Wharton Jelly-derived MSCs”. The injected therapeutic dose was 1 × 106 cells/kg, 1 × 107 cells/kg, 1 × 105 cells/kg, and 1 million cells/kg as per the evidence from the different studies. Studies focused on demographic variables, clinical symptoms, laboratory tests, Comorbidities, respiratory measures, concomitant therapies, Sequential Organ Failure Assessment score, mechanical ventilation, body mass index, adverse events, inflammatory markers, and PaO2/FiO2 ratio were all recorded as study characteristics. Conclusion: Clinical evidence on MSC’s therapeutic applications during COVID-19 pandemic has proven to be a promising therapy for COVID-19 patient recovery with no consequences and applied as a routine treatment for challenging ailments.

1 August 2023 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
UKUsha Rani Kandula
Usha Rani Kandula
TTTechane Sisay Tuji
Techane Sisay Tuji
AAAnwar Abdulwahed
Anwar Abdulwahed
KDKetema Diriba
Ketema Diriba
KLKassech Leta
Kassech Leta
BABirhanu Alemu
Birhanu Alemu
Severe acute respiratory syndrome-Coronavirus-2(SARS-CoV-2) is very susceptible to transmission, and caused Coronavirus-19 (COVID-19), by spreading throughout the globe in early 2020 after starting in Wuhan, China in late 2019. Intensive care unit (ICU) COVID-19 patients experienced elevated fatality rates as a result of the COVID-19 pandemic. It is also anticipated that, the bacterial co-infection will cause a wave of subsequent bacterial illnesses. A significant infection causes morbidity in critically ill patients with COVID-19, is known as ventilator-associated pneumonia (VAP). A public health emergency has been proclaimed for COVID-19 by the World Health Organization (WHO). As per WHO, more than 113 million COVID-19 cases have been confirmed, and there have been about 2.5 million fatalities. Early research has shown that nosocomial pneumonia, particularly VAP, is significantly more common in people with severe SARS-CoV-2 infections. ICU patients frequently experience Acinetobacter baumannii (AbB) infections, while Aspergillus species are the fungi most frequently responsible for VAP. The review emphasizes the most prevalent microorganisms that caused infections to arise among hospitalized patients throughout the COVID-19 era. The literature identified AbB, Klebsiella pneumonia (KP), Aspergillus, Enterobacter cloacae (EC), Stenotrophomonas maltophilia (SmM), Staphylococcus aureus (SA), Streptococcus pneumonia (SP), Haemophilus influenza (HI), Enterococcus faecalis (EF), Escherichia coli (EC), Candida albicans (CA), PA (PA), Serratia marcescens(SM), Burkholderia gladioli (BG), Mucor spp. (MS), Rhizopus spp. (RS), Cryptococcus Neoformans (CN), Paracoccus yeei (PY). This review may help the health sectors to identify and focus on VAP causative organisms during COVID-19 pandemic period, for the early initiation of prompt therapeutic management.